Get ready for a deep dive into a fascinating yet concerning topic: the rise of macrolide resistance in Mycoplasma pneumoniae infections, and how it's impacting communities worldwide. This is a story of scientific discovery and the ongoing battle against a resilient pathogen.
Mycoplasma pneumoniae, a notorious cause of respiratory infections, has been making headlines due to its increased prevalence post-COVID-19 pandemic restrictions. In Ontario, Canada, we've witnessed an unprecedented surge in detection, with positivity rates reaching a staggering 30% in 2024. This outbreak has sparked a critical investigation into macrolide resistance and the genetic makeup of this pathogen.
Our study, conducted in Hamilton, Ontario, delves into the rates of macrolide resistance and the P1 cytadhesin types of M. pneumoniae during the 2024-2025 outbreak. We compared these findings with strains collected before the COVID-19 pandemic to understand the evolution of this pathogen.
Here's a breakdown of our key findings:
Positivity rates for M. pneumoniae skyrocketed in 2024, with an average of 14.2% of patients testing positive, compared to less than 0.5% in 2022 and 2023. This surge began in May 2024 and peaked in September, with a positivity rate of 22.5%.
Macrolide resistance rates varied monthly, accounting for 11.8% of all positive samples during our study period. The highest resistance rate of 50% was observed in July 2024. PCR genotyping identified a single-nucleotide polymorphism (SNP) associated with macrolide resistance: A2063G, which confers high-level resistance.
M. pneumoniae detection rates were significantly higher in children aged 5 to 18 years, at around 20%. Interestingly, the macrolide resistance rate in this age group was not significantly different from other age groups, except for those aged over 65, who had a significantly higher resistance rate of 50%. This could be linked to the higher likelihood of macrolide use in elderly patients.
When comparing macrolide resistance rates between the pre-pandemic (2013-2020) and post-pandemic (2024-2025) periods, we found no significant difference. However, we did observe a major shift in the molecular epidemiology of M. pneumoniae.
Through P1 typing, we found that 81% of M. pneumoniae strains belonged to the P1-1 type, with the remaining 19.1% being P1-2. The P1-1 type had a significantly higher macrolide resistance rate of 29.9%, compared to 7.7% in the P1-2 type. This finding contradicts previous studies that reported no association between macrolide resistance and P1 types.
Phylogenetic analysis revealed that all P1-1 type strains, including those from 2017-2020, clustered together on a distinct branch, separate from strains reported over 10 years ago in Ontario. This suggests an evolution of the RepMP4 region of P1-1-type strains over time.
Among the P1-2 types, we detected variants 2k, 2b, and 2g/2j in samples collected during 2013-2020. There was a predominance of 2g/2j variants in both periods, but the percentage of 2c/2k variants increased during 2024-2025.
Our study has some limitations. P1 typing was performed on a subset of samples, and variant analysis relied solely on RepMP4 sequencing. Additionally, our data represents only the Hamilton region, and regional variations across Ontario cannot be excluded.
Despite these limitations, our findings provide a critical snapshot of macrolide resistance rates and P1 genotypes of M. pneumoniae strains in Hamilton nearly a decade after the last provincial report. While macrolide resistance rates appear stable, the shift in P1 cytadhesin types is significant and warrants attention from clinicians and public health professionals.
This study highlights the ongoing challenge of managing respiratory infections caused by M. pneumoniae in Ontario. As we navigate the post-pandemic world, it's crucial to stay vigilant and adapt our strategies to combat this evolving pathogen.
What are your thoughts on these findings? Do you think the shift in P1 cytadhesin types could impact treatment strategies? We'd love to hear your insights and opinions in the comments below!
